Literature DB >> 9647910

The case-time-control design: further assumptions and conditions.

S Suissa1.   

Abstract

The case-time-control design is a strategy that was developed to tackle the problem of confounding by indication in the nonexperimental assessment of intended or known effects of drugs. By using subjects as their own controls, the case-time-control design, under an explicitly defined model, eliminates the biasing effect of unmeasured confounding factors in the situation where exposure varies over time. The correct application of this design is based on a specific model that contains inherent assumptions and imposes certain conditions for the approach to be valid. In a recent article, Greenland questioned the validity of the case-time-control design by presenting several "counterexamples." In this paper, we review the assumptions inherent to the validity of the case-time-control model. We show that the presumed counterexamples are not what they are claimed to be, simply because they do not conform to the logistic model explicitly underlying the case-time-control approach. These examples are shown to arise from an alternative model that includes a confounder by period interaction, a term expressly avoided in the case-time-control model. When the data from these examples are modified to satisfy the correct model, the resulting case-time-control estimates of the treatment odds ratio are exactly 2, the true treatment effect. We clarify the necessity of this assumption in the context of matching in epidemiology. We also discuss briefly the assumptions of conditional independence and carryover effects.

Mesh:

Year:  1998        PMID: 9647910

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  24 in total

1.  How do we best detect toxic effects of drugs taken during pregnancy? A EuroMap paper.

Authors:  Jørn Olsen; Andrew Czeizel; Henrik Toft Sørensen; Gunnar Lauge Nielsen; Lolkje T W de Jong van den Berg; Lorentz M Irgens; Charlotte Olesen; Lars Pedersen; Helle Larsen; Rolv T Lie; Corinne S de Vries; Ulf Bergman
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 2.  Appending epidemiological studies to conventional case-control studies (hybride case-control studies).

Authors:  Andreas Stang; Karl-Heinz Jöckel
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

Review 3.  Developments in post-marketing comparative effectiveness research.

Authors:  S Schneeweiss
Journal:  Clin Pharmacol Ther       Date:  2007-06-06       Impact factor: 6.875

4.  Nonsteroidal Anti-Inflammatory Drugs and Risk of First Hospitalization for Heart Failure in Patients with No History of Heart Failure: A Population-Based Case-Crossover Study.

Authors:  Sung-Po Huang; Yao-Chun Wen; Shih-Tsung Huang; Chih-Wan Lin; Tzung-Dau Wang; Fei-Yuan Hsiao
Journal:  Drug Saf       Date:  2019-01       Impact factor: 5.606

5.  "First-wave" bias when conducting active safety monitoring of newly marketed medications with outcome-indexed self-controlled designs.

Authors:  Shirley V Wang; Sebastian Schneeweiss; Malcolm Maclure; Joshua J Gagne
Journal:  Am J Epidemiol       Date:  2014-08-01       Impact factor: 4.897

6.  Exchangeability in the case-crossover design.

Authors:  Murray A Mittleman; Elizabeth Mostofsky
Journal:  Int J Epidemiol       Date:  2014-04-22       Impact factor: 7.196

7.  Impact of specific Beers Criteria medications on associations between drug exposure and unplanned hospitalisation in elderly patients taking high-risk drugs: a case-time-control study in Western Australia.

Authors:  Sylvie D Price; C D'Arcy J Holman; Frank M Sanfilippo; Jon D Emery
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

8.  Effect of macrolide and fluoroquinolone antibacterials on the risk of ventricular arrhythmia and cardiac arrest: an observational study in Italy using case-control, case-crossover and case-time-control designs.

Authors:  Antonella Zambon; Hernan Polo Friz; Paolo Contiero; Giovanni Corrao
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

9.  Risk of a thrombotic event after the 6-week postpartum period.

Authors:  Hooman Kamel; Babak B Navi; Nandita Sriram; Dominic A Hovsepian; Richard B Devereux; Mitchell S V Elkind
Journal:  N Engl J Med       Date:  2014-02-13       Impact factor: 91.245

10.  Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study.

Authors:  Laura Y Park-Wyllie; Muhammad M Mamdani; Ping Li; Sudeep S Gill; Andreas Laupacis; David N Juurlink
Journal:  PLoS Med       Date:  2009-09-29       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.